Alfasigma S.p.A. is an Italy‑headquartered pharmaceutical company formed in 2016 through the combination of Alfa Wassermann and Sigma‑Tau. It researches, develops, manufactures, and markets prescription medicines, over‑the‑counter products, and nutraceuticals. The company’s portfolio and R&D are concentrated in gastroenterology and related metabolic and vascular conditions, alongside selected specialty areas.
Alfasigma operates globally through subsidiaries and partners across Europe, the Americas, and Asia, with R&D and manufacturing sites primarily in Italy. Its activities span small‑molecule drug development, clinical research, and the industrial production and distribution of finished pharmaceuticals, with additional growth supported by in‑licensing and collaboration agreements.
FDA approved linerixibat for cholestatic pruritus in adults with PBC after GLISTEN phase III showed rapid, sustained itch and sleep improvements. Common AEs: diarrhea, abdominal pain.
Alfasigma gains global rights to develop and market linerixibat for cholestatic pruritus in PBC. GSK to receive payments and royalties. Regulatory reviews are ongoing.
